[go: up one dir, main page]

BR9808157A - Processo de inibição do desenvolvimento de células tumorais e de tumor e composição farmacêutica - Google Patents

Processo de inibição do desenvolvimento de células tumorais e de tumor e composição farmacêutica

Info

Publication number
BR9808157A
BR9808157A BR9808157-8A BR9808157A BR9808157A BR 9808157 A BR9808157 A BR 9808157A BR 9808157 A BR9808157 A BR 9808157A BR 9808157 A BR9808157 A BR 9808157A
Authority
BR
Brazil
Prior art keywords
tumor
pharmaceutical composition
inhibition
cell development
tumor cell
Prior art date
Application number
BR9808157-8A
Other languages
English (en)
Inventor
Charles E Elson
Original Assignee
Wisconsin Alumni Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Res Found filed Critical Wisconsin Alumni Res Found
Publication of BR9808157A publication Critical patent/BR9808157A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355Tocopherols, e.g. vitamin E
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

''PROCESSO DE INIBIçãO DO DESENVOLVIMENTO DE CéLULAS TUMORAIS E DE TUMOR E COMPOSIçãO FARMACêUTICA''. Um processo para inibir o desenvolvimento de células tumorais é apresentado. Em uma modalidade, este processo compreende a etapa de expor as células tumorais a uma quantidade eficaz de uma composição compreendendo pelo menos dois compostos selecionados do grupo consistindo de tocotrienóis, estatinas e iononas.
BR9808157-8A 1997-03-04 1998-02-23 Processo de inibição do desenvolvimento de células tumorais e de tumor e composição farmacêutica BR9808157A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3979097P 1997-03-04 1997-03-04
PCT/US1998/003470 WO1998038993A1 (en) 1997-03-04 1998-02-23 Method of suppressing tumor growth with combinations of isoprenoids and statins

Publications (1)

Publication Number Publication Date
BR9808157A true BR9808157A (pt) 2000-03-28

Family

ID=21907353

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9808157-8A BR9808157A (pt) 1997-03-04 1998-02-23 Processo de inibição do desenvolvimento de células tumorais e de tumor e composição farmacêutica

Country Status (13)

Country Link
US (2) US6133312A (pt)
EP (1) EP0986383A1 (pt)
JP (1) JP2001507363A (pt)
KR (1) KR20000075919A (pt)
AU (1) AU729355B2 (pt)
BR (1) BR9808157A (pt)
CA (1) CA2283333A1 (pt)
HU (1) HUP0002049A2 (pt)
IL (1) IL131628A0 (pt)
NO (1) NO994309L (pt)
PL (1) PL335506A1 (pt)
RU (1) RU2179440C2 (pt)
WO (1) WO1998038993A1 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
US6239114B1 (en) * 1997-09-26 2001-05-29 Kgk Synergize Compositions and methods for treatment of neoplastic diseases with combinations of limonoids, flavonoids and tocotrienols
US6251400B1 (en) * 1997-09-26 2001-06-26 Kgk Synergize Inc Compositions and methods of treatment of neoplastic diseases and hypercholesterolemia with citrus limonoids and flavonoids and tocotrienols
US6703384B2 (en) 1998-09-23 2004-03-09 Research Development Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
MXPA01005545A (es) * 1998-12-07 2003-07-14 Ecosmart Technologies Inc Composicion y metodo para tratamiento de cancer que usan moduladores de transduccion de senales y aceites esenciales vegetales naturales.
ATE382615T1 (de) * 2000-02-11 2008-01-15 Res Dev Foundation Tocopherole, tocotrienole, andere chrome und seitenketten-derivate und ihre verwendung
US20030104090A1 (en) * 2000-05-05 2003-06-05 Levy Pedro E. Supplements containing annatto extracts and carotenoids and methods for using the same
US6566397B2 (en) 2000-07-18 2003-05-20 Wisconsin Alumni Research Foundation Acyclic isoprenoid ether derivatives as chemotherapeutics
US20030236301A1 (en) * 2001-12-19 2003-12-25 Bob Sanders Liposomal delivery of vitamin E based compounds
US7074825B2 (en) * 2002-03-07 2006-07-11 Huanbiao Mo Composition and method for treating cancer
US7989006B2 (en) * 2003-04-08 2011-08-02 American River Nutrition, Inc. Annatto extract compositions, including geranyl geraniols and methods of use
EP1624880B1 (en) * 2003-04-08 2018-12-19 Barrie Tan Annatto extract compositions, including geranyl geraniols for use in the decrease in the blood level of triglyceride
US20050037102A1 (en) * 2003-07-18 2005-02-17 Barrie Tan Annatto extract compositions including tocotrienols and tocopherols and methods of use
WO2005094814A1 (ja) * 2004-03-31 2005-10-13 Kowa Co., Ltd. 外用剤
ATE491447T1 (de) * 2004-05-26 2011-01-15 Kgk Synergize Inc Flavonoide und tocotrienole enthaltende zusammensetzungen und deren verwendungen
DE102006008074B4 (de) * 2006-02-22 2013-08-14 RUHR-UNIVERSITäT BOCHUM Behandlung von Krebs mit Geruchsrezeptor-Liganden
US8288369B2 (en) * 2006-06-27 2012-10-16 University Of South Florida Delta-tocotrienol treatment and prevention of pancreatic cancer
US20090004290A1 (en) * 2007-06-30 2009-01-01 Voelker Kirk G Red yeast rice compound for cancer chemoprevention
WO2010124223A1 (en) * 2009-04-23 2010-10-28 First Tech International Limited Anti-cancer tocotrienol analogues and associated methods
EP2473044B1 (en) * 2009-09-01 2014-04-02 First Tech International Limited Tocotrienol compositions
WO2011097481A1 (en) * 2010-02-05 2011-08-11 First Tech International Limited Tocotrienol esters
US20130158106A1 (en) 2010-06-02 2013-06-20 The United States Of America As Represented By The Department Of Veteran Affairs Tocopherol derivatives and methods of use
US9132117B2 (en) 2013-06-17 2015-09-15 Kgk Synergize, Inc Compositions and methods for glycemic control of subjects with impaired fasting glucose
EP3043807B1 (en) 2013-09-13 2023-11-01 BioVentures, LLC Preparation and use of a composition for prevention and mitigation of the effects of radiation
US20160324914A1 (en) 2015-05-05 2016-11-10 Tocol Pharmaceuticals, Llc Use of rice bran oil distillate extract for prevention and mitigation of the effects of radiation

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US33885A (en) * 1861-12-10 Improvement
US34617A (en) * 1862-03-04 Improved cylinder for grain scouring and thrashing machines
USRE33885E (en) 1975-11-03 1992-04-14 The Procter & Gamble Company Compositions for inhibiting absorption of cholesterol
US4005196A (en) 1976-02-12 1977-01-25 The Procter & Gamble Company Vitaminized compositions for treating hypercholesterolemia
US4789554A (en) * 1985-12-05 1988-12-06 The Procter & Gamble Company High temperature vacuum steam distillation process to purify and increase the frylife of edible oils
AU618791B2 (en) * 1988-03-16 1992-01-09 Bioindustry Development Centre Production of high concentration tocopherols and tocotrienols from palm oil by-product
DE3903991A1 (de) * 1989-02-10 1990-08-30 Basf Ag Phenylhydrazone des (beta)-jonons, ihre herstellung und daraus hergestellte arzneimittel und kosmetika
US5217992A (en) * 1989-10-04 1993-06-08 Bristol-Myers Squibb Company Tocotrienols in the treatment of hypercholesterolemia, hyperlipidemia and thromboembolic disorders
US5554647A (en) * 1989-10-12 1996-09-10 Perricone; Nicholas V. Method and compositions for treatment and/or prevention of skin damage and aging
US5574063A (en) * 1989-10-12 1996-11-12 Perricone; Nicholas V. Method and compositions for topical application of ascorbic acid fatty acid esters for treatment and/or prevention of skin damage
US5157132A (en) * 1990-05-18 1992-10-20 Carotech Associates Integrated process for recovery of carotenoids and tocotrienols from oil
US5393776A (en) * 1990-09-14 1995-02-28 Bristol-Myers Squibb Company Tocotrienol analogs in the treatment of hypercholesterolemia and hyperlipidemia
US5204373A (en) * 1991-08-26 1993-04-20 Bristol-Myers Squibb Company Farnesylated tetrahydro-naphthalenols as hypolipidemic agents
US5605930A (en) * 1991-10-21 1997-02-25 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for treating and preventing pathologies including cancer
JPH07504887A (ja) * 1991-11-22 1995-06-01 リポジェニックス,インコーポレイテッド トコトリエノールおよびトコトリエノール様化合物ならびにこれらを使用する方法
WO1993016690A1 (en) * 1992-02-25 1993-09-02 Warner-Lambert Company Cytoprotective compositions containing pyruvate and antioxidants
IL104736A0 (en) * 1992-03-27 1993-06-10 Zeagen Inc Method for producing beta-carotene using a fungal mated culture
CA2135312C (en) * 1992-05-13 2006-09-26 Charles Myers Use of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme a reductase as a modality in cancer therapy
US5376361A (en) * 1993-01-13 1994-12-27 Perricone; Nicholas V. Method and compositions for topical application to the skin for prevention and/or treatment of radiation-induced skin damage
US5391765A (en) * 1993-04-16 1995-02-21 Bristol-Myers Squibb Company Cholesterol lowering/antioxidant nitroxides
US5411969A (en) * 1993-04-16 1995-05-02 Bristol-Myers Squibb Company Antihyperlipidemic/antioxidant dihydroquinolines
US5475029A (en) * 1993-07-08 1995-12-12 The Board Of Trustees Of The Leland Stanford Junior University Farnesyl compounds as cholesterol lowering agents
US5500154A (en) * 1994-10-20 1996-03-19 The Procter & Gamble Company Detergent compositions containing enduring perfume

Also Published As

Publication number Publication date
IL131628A0 (en) 2001-01-28
CA2283333A1 (en) 1998-09-11
JP2001507363A (ja) 2001-06-05
US6441029B1 (en) 2002-08-27
HUP0002049A2 (hu) 2000-10-28
WO1998038993A1 (en) 1998-09-11
KR20000075919A (ko) 2000-12-26
US6133312A (en) 2000-10-17
NO994309D0 (no) 1999-09-03
PL335506A1 (en) 2000-04-25
AU6335198A (en) 1998-09-22
NO994309L (no) 1999-09-03
AU729355B2 (en) 2001-02-01
EP0986383A1 (en) 2000-03-22
RU2179440C2 (ru) 2002-02-20

Similar Documents

Publication Publication Date Title
BR9808157A (pt) Processo de inibição do desenvolvimento de células tumorais e de tumor e composição farmacêutica
ES2193508T3 (es) Ftalizinonas.
BR9811099A (pt) Inibidores de urocinase
TR199800585T2 (xx) COX-2 �nhibit�rleri Olarak (Metils�lfonil)Fenil-2-(5H)-Furanonlar.
CO5050303A1 (es) Composicion farmaceutica para tratar infecciones virales y metodos para su preparacion su aplicacion
BR9509472A (pt) Processo para biooxidação de montão de minério
DK0840732T3 (da) Substituerede benzolactamforbindelser som substans P-antagonister
BR9504224A (pt) Processo para prevenir que uma chamada ativa seja interrompida
BR0007500A (pt) Composto triazol, fármaco, e, uso do composto
DK0722736T3 (da) Topisk sammensætning indeholdende en antagonist for substans P
BR9814361A (pt) Inibição de quinase raf usando uréiasheterocìclicas substituìdas por arila eheteroarila
BR9913255A (pt) Composto, composição farmacêutica, processo de tratamento de uma condição de doença mediada por metaloproteinase, processo para preparar um composto, e, uso de um composto
FI970069L (fi) Menetelmä (2R-3S)-(4-asetoksi-2alfa-bentsoyylioksi-5beta,20-epoksi-1,7beta,10beta-trihydroksi-9-oksotaks-11-en-13alfa-yyli)-3-tert-butoksikarbonyyliamino-3-fenyyli-2-hydroksipropionaatin trihydraatin valmistamiseksi
BR0010166A (pt) Composto modulador de ace-2, composto inibidor de ace-2, métodos para o tratamento de um estado associado a ace-2 em um paciente e para inibir a hidrólise de um peptìdeo de marcação de ace-2, e, composição farmacêutica
DE69603089D1 (de) Zusammensetzung zur behandlung von mauerwerk
BR9911491A (pt) Processo de tratamento de uma superfìcie metálica para aumentar a resistência contra corrosão, e, uso de uma solução de tratamento
EA199900421A1 (ru) Бензонафтиридины в качестве бронхиальных терапевтических средств
FI951856L (fi) Farmaseuttinen koostumus osteoporoosin hoitamiseksi
ES2147399T3 (es) Nuevos derivados de 2,3,5-trimetil-4-hidroxianilidas, su preparacion y su aplicacion terapeutica.
DE60009665D1 (de) Zusammensetzungen zur behandlung von entzündungsreaktionen
ES2221950T3 (es) Dihidrobenzofurano y compuestos relacionados utiles como agentes anti-inflamatorios.
BR9910678A (pt) Composto, composição farmacêutica, método para traramento ou prevenção de uma doença inflamatória, método para tratamento de uma condição ou uma doença mediada por mmps, tnf, agrecanase, ou um composto dos mesmos, em um mamìfero, método de redução de nìveis de tnf em pacientes, sem a inibição de mmps, método para tratamento de uma condição ou uma doença e uso de um novo composto
BR9407257A (pt) Composto do tipo bis-naftalimida composição farmacêutica processo para tratamento de um tumor em mamifero uso do composto do tipo bis-naftalimida e processo para a preparação compostos do tipo bis-naftalimida
BR0111897A (pt) Composto, método para tratar um indivìduo afligido por alguns distúrbios dos sistemas nervosos periférico e central, composição farmacêutica, e, uso de um composto
BR9911559A (pt) Processo para a preparação de um composto, composto, processo para o tratamento de tumores resistentes a medicamento múltiplo, uso de um composto, e, agente e composição para tratar tumores resistentes a medicamento múltiplo.

Legal Events

Date Code Title Description
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 NA RPI 1891 DE 03/04/2007